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Use of propensity score matching 
to create counterfactual group 
to assess potential HIV prevention 
interventions
Andrew Abaasa1,2*, Yunia Mayanja1, Gershim Asiki3,4, Matt A. Price5,6, Patricia E. Fast5,7, 
Eugene Ruzagira1,2, Pontiano Kaleebu1,2 & Jim Todd2 
The design of HIV prevention trials in the context of effective HIV preventive methods is a challenge. 
Alternate designs, including using non-randomised ‘observational control arms’ have been proposed. 
We used HIV simulated vaccine efficacy trials (SiVETs) to show pitfalls that may arise from using such 
observational controls and suggest how to conduct the analysis in the face of the pitfalls. Two SiVETs 
were nested within previously established observational cohorts of fisherfolk (FF) and female sex 
workers (FSW) in Uganda. SiVET participants received a licensed Hepatitis B vaccine in a schedule (0, 
1 and 6 months) similar to that for a possible HIV vaccine efficacy trial. All participants received HIV 
counselling and testing every quarter for one year to assess HIV incidence rate ratio (IRR) between 
SiVET and non-SiVET (observational data). Propensity scores, conditional on baseline characteristics 
were calculated for SiVET participation and matched between SiVET and non-SiVET in the period 
before and during the SiVET study. We compared IRR before and after propensity score matching 
(PSM). In total, 3989 participants were enrolled into observational cohorts prior to SiVET, (1575 
FF prior to Jul 2012 and 2414 FSW prior to Aug 2014). SiVET enrolled 572 participants (Jul 2012 to 
Apr 2014 in FF and Aug 2014 to Apr 2017 in FSW), with 953 non-SiVET participants observed in the 
SiVET concurrent period and 2928 from the pre-SiVET period (before Jul 2012 in FF or before Apr 
2014 in FSW). Imbalances in baseline characteristics were observed between SiVET and non-SiVET 
participants in both periods before PSM. Similarly, HIV incidence was lower in SiVET than non-SiVET; 
SiVET-concurrent period, IRR = 0.59, 95% CI 0.31–0.68, p = 0.033 and pre-SiVET period, IRR = 0.77, 
95% CI 0.43–1.29, p = 0.161. After PSM, participants baseline characteristics were comparable and 
there were minimal differences in HIV incidence between SiVET and non-SiVET participants. The 
process of screening for eligibility for efficacy trial selects participants with baseline characteristics 
different from the source population, confounding any observed differences in HIV incidence. 
Propensity score matching can be a useful tool to adjust the imbalance in the measured participants’ 
baseline characteristics creating a counterfactual group to estimate the effect of interventions on HIV 
incidence.
Globally, new HIV infections continue to occur particularly in Sub Saharan Africa (SSA)1. This is despite of the 
available effective biomedical and behavioral HIV prevention interventions. In SSA, sub-optimal adherence is 
cited as a key reason for the ineffectiveness of the available HIV prevention  interventions2. The long-term hope 
for controlling the HIV pandemic is an effective and affordable  vaccine3, an antibody  injection4 or long acting 
 drug5. The vaccines and other products being developed will have to go through assessment in efficacy trials, 
which will become increasingly costly, as future trials must offer HIV combination prevention packages that will 
reduce HIV incidence, hence taking a longer time to get definitive results.
The HIV prevention field is considering how observational data from existing cohorts or earlier trials can 
be used to assess the effect of new  interventions6,7. However, there are clear differences in outcomes between 
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participants who join trials and those that do not. This could be due to selection bias, the quality of care, or higher 
study completion  rates8–10. Furthermore, the HIV prevention field is quickly evolving with many healthcare inno-
vations making data from earlier trials less relevant. Comparing HIV incidence from clinical trials to that from 
observational data, or data from earlier trials could lead to an overestimate of efficacy. Other investigators have 
proposed using the Averted Infections Ratio (AIR) concept (i.e., the rate difference between hypothetical placebo 
and experimental arms divided by the rate difference between hypothetical placebo and active control arms)11. 
The challenge with this approach is in the estimation of the HIV incidence in the hypothetical placebo arm. 
With the AIR approach, investigators might propose use of incidence from, e.g., a run-in period in a registration 
cohort, epidemiological surveillance systems or sexually transmitted infection incidence from another trial as a 
surrogate for hypothetical placebo arm HIV  incidence11. These sources of incidence data introduce significant 
uncertainty and are likely to provide a biased estimate due to population and study differences.
Propensity score (PS), a statistical technique that attempts to estimate the effect of  treatment12,13 could be a 
useful strategy to reduce the uncertainty in estimating hypothetical placebo HIV incidence. Propensity score 
provides the probability of treatment assignment conditional on measured baseline characteristics. This allows 
us to design and analyze an observational study mimicking some of the attributes of a randomized controlled 
trial. Propensity Score Matching (PSM) will give a distribution of measured baseline covariates that is similar 
between treated and untreated subjects. By doing this, we could create a non-randomised, but comparable 
counterfactual group, which provides a less biased HIV incidence for a hypothetical placebo arm. A similar 
approach has been used previously to balance baseline characteristics between trials and observational data or 
other studies to estimate treatment  effects14–17.
The simulated vaccine efficacy trial (SiVET) concept has been suggested to provide trial context data, through 
a ‘‘simulated” trial using a commercially licensed  vaccine18,19. This concept additionally helps to inform the design 
and sample size estimation for clinical  trials20. Between July 2012 and August 2017 two SiVETs were nested 
within observational cohorts of female sex workers and fisherfolk sub-populations in Uganda to; (1) provide an 
HIV vaccine efficacy trial platform, (2) estimate HIV incidence, that would be used to plan a future HIV vaccine 
efficacy trial in these distinct key populations.
In this paper we use data from three observational cohorts (two in the fishing communities and one among 
female sex workers, all in Uganda) and their respective, nested HIV simulated vaccine efficacy trials (SiVETs) 
to; (a) create a counterfactual group (i.e., a non-randomised comparison arm) from observational data that is 
comparable to SiVET and (b) estimate and compare HIV incidence between observational cohorts and SiVETs 
before and after propensity score matching in two distinct key populations.
Methods
Design. SiVETs nested within longitudinal observational cohorts of fisherfolk (FF) and female sex worker 
(FSW) in Uganda.
Setting. The fisherfolk observational cohorts (OBC) recruited from fishing communities on the shoreline 
of Lake Victoria in Entebbe and Masaka, about 40 km South and 100 km West of Kampala, Uganda’s capital 
respectively and the SiVET in this population was nested in the observational cohort in Masaka. The main eco-
nomic activity is fishing but other occupations such as fish processing, small-scale businesses, entertainment etc. 
support the fishing activity. This population is characterised by very high HIV prevalence, 20–30%21 and annual 
incidence, 3–11%22, with more than 50% reporting frequent high risk sexual  behaviour23.
The FSW population’s observational cohort was located within Kampala city; on Mengo hill near the Kam-
pala city center. Women in sex work operate from HIV hotspots defined as nightclubs, entertainment facilities, 
restaurants/hotel, lodges and bars conducive for meeting male clients. Similarly, the prevalence and annual 
incidence of HIV are reported to be very high 37%(24) and 3%8 respectively and > 90% of these women report 
frequent high risk sexual  behaviour23.
Description of observational cohorts. Data from three observational cohorts; two-FF and one-FSW 
conducted respectively from February 2009 to April 2015 and from April 2008-April 2017 were used in this anal-
ysis, Fig. 1. In the first fisherfolk cohort (February 2009 to December 2011), study staff provided HIV counselling 
and testing (HCT) to potential participants and those found to be HIV negative, aged 18–49 years were enrolled 
into an observational cohort at a clinic established in each of five participating fishing communities. Repeat HCT 
was performed every 6-months for 18 months. The primary aims of this observational cohort was to determine 
the feasibility of enrolling and following fisherfolk in an observational cohort and to determine HIV incidence. 
The second fisherfolk cohort, (January 2012 to April 2015) was similar to the first fisherfolk cohort with the fol-
lowing exceptions: (1) participants had to travel from the landing sites to the research clinic in Masaka Town, a 
distance of approximately 40 km, to attend study visits; (2) repeat HCT was conducted quarterly; (3) extra aim 
of maintaining a pool of participants for future HIV prevention trials.
The FSW cohort initially recruited women from one administrative (Makindye) division of Kampala city until 
2014 when the protocol was amended to include all the city’s five divisions. Trained study fieldworkers visited 
HIV hotspots, provided study information to prospective participants, and invited them to the study clinic for 
screening and possible enrolment. At the clinic, women received HCT and those found to be HIV negative were 
enrolled. The aims of this cohort and participant follow up schedules were similar to those of the second fisherfolk 
cohort above. Details of the FF & FSW cohorts have been published  previously8,22,24–26.
Description of SiVETs. To prepare the research teams for the rigors of clinical trials, SiVETs were nested 
in the observational cohorts described above (one in each of FF and FSW), administering hepatitis B vaccine 
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(GlaxoSmithKline Biologicals Rixensart, Belgium) as a proxy for an experimental HIV vaccine. Participants 
that had been enrolled in the observational cohorts ≥ 3 months and ≤ 18 months were consecutively screened 
and enrolled into SiVET, from July 2012 to April 2014 in the second fisherfolk cohort and from August 2014 to 
April 2017 in the FSW cohort. SiVET participants received a licensed Hepatitis B vaccine injection at 0, 1 and 
6 months mimicking a possible schedule for an actual HIV vaccine efficacy trial. They also underwent HCT 
every quarter for one year. SiVETs details have also been previously  published25–27.
Data stratification. We divided the observational cohort data into two periods (a) the Pre-SiVET observational 
cohort (non-SiVET data) made up of enrollment and follow up data before rollout of the SiVET protocol in both 
the FF and FSW communities and (b) observational cohort also codenamed non-SiVET data for the purpose of 
the comparisons in this paper, collected in the SiVET concurrent period. This is comprising of all the data col-
lected in the 12 months of observational cohort in the SiVET period, mutually exclusive, Fig. 1.
Key evaluations. 
 i. We compared baseline characteristics of the participants in the SiVET to those in observational cohort 
(non-SiVET cohort); (a) in the pre-SiVET period, (b) in the SiVET period, all before propensity score 
matching.
 ii. Repeated evaluation (i) above after propensity score matching.
 iii. We compared HIV incidence in the SiVET to that in the non-SiVET; (c) in the pre-SiVET period, (d) in 
the SiVET period, all before propensity score matching.
 iv. Repeated evaluation (iii) above after propensity score matching.
Role of SiVET data. In these analyses, the SiVET data were used to mimic a placebo arm of an actual HIV 
vaccine efficacy trial since the hepatitis B vaccine used in the SiVETs had no effect on HIV susceptibility, and to 
facilitate the creation of a similar counterfactual trial arm from non-SiVET observational data.
HIV testing. Largely, HIV testing was performed using a single antibody rapid test by Alere Determine HIV-
1/2 (Alere Medical Co Ltd, Matsuhidai, Matsudo-shi, Chiba, Japan). Samples that turned out positive under-
went a confirmation test using two parallel enzyme linked immunosorbent assay (ELISA) tests (Murex Biotech 
Limited, Dartford, United Kingdom, and Vironostika, BioMérieux boxtel, The Netherlands). Discordant HIV 
results were confirmed by either Statpak (Chembio Diagnostic Systems Inc., USA) or Western Blot (Cambridge 
Biotech, USA).
Data management and statistical methods. Observational cohort data and SiVET in the fisherfolk 
were captured in MS Access 2003 database (Microsoft Corporation, Redmond, WA), while SiVET data in the 
FSW were managed using OpenClinica 3.5 (Waltham, MA). All data were analysed in STATA 15.0 (Stata Corp, 
College Station, TX, USA). The observational cohort datasets were stratified into two periods, (1) non-SiVET in 
the pre-SiVET period; data collected from the date of initiation of observational cohort to the date of initiation 
of SiVET protocol in a given source population (FF or FSW). (2) Non-SiVET in the SiVET concurrent; data col-
lected from the date SiVET began enrolling to the date of the last SiVET participant clinic visit.
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Variable categorizations. We categorized source population as fisherfolk (FF) or female sex worker (FSW), reli-
gion as Christian (including Catholic, Anglicans, Pentecostals, seventh day Adventists) or Muslim, and marital 
status as single never married (if one had never lived with a partner in any sexual relationship) or currently/pre-
viously married (including married polygamous, monogamous, widowed or separated). In all the cohorts and 
SiVETs, alcohol use was defined as “Yes” if a participant reported using alcohol in the three months preceding 
the interview or “No” if a participant reported not using alcohol in the same period.
Calculating the propensity score. Logit models, in which SiVET assignment status was regressed on measured 
baseline characteristics were fitted to determine the propensity scores (probability of selection into SiVET condi-
tional on measured baseline characteristics) stratified by period (pre-SiVET or SiVET concurrent). We matched 
on the following variables; source population, sex, age group, ethnicity, education level, marital status, duration 
of stay in the community, number of sexual partners in the last three months and alcohol use.
Propensity score matching. We performed 1:1 propensity score matching without replacement within a caliper 
width of 0.2 between SiVET and non-SiVET in the pre-SiVET, and in the SiVET concurrent periods to ensure 
a balance in baseline characteristics. Matching using a caliper width of 0.2 of the pooled standard deviation of 
the logit of the propensity score is considered to afford superior performance in the estimation of treatment 
 effects28. We considered less than 20% difference in covariates after matching as indicative of good  matching29. 
Participants in SiVET for whom there was no match in the non-SiVET were excluded from the propensity score 
matched analysis. We used Chi-square tests to compare the baseline characteristics of participants in SiVET to 
those in observational cohorts before and after propensity score matching stratified by the period. We estimated 
the standardized differences before and after propensity score matching comparing covariate values for par-
ticipants in SiVET to those in non-SiVET in either period and illustrated these graphically. We compared HIV 
incidence between SiVET and non-SiVET in each period before and after propensity score matching.
HIV incidence. HIV incidence was determined as total number of HIV positive cases divided by total person 
years at risk (PYAR) expressed as per 100 PYAR. PYAR were calculated as sum of the time from study specific 
participant enrolment date to the date of the last HIV seronegative result or an estimated date of HIV infection. 
The date of HIV infection was defined as a random (multiple imputation) date between last HIV-negative and 
the first HIV-positive result dates.
Ethical approval and consent to participate. The Uganda Virus Research Institute (UVRI) Research 
and Ethics Committee and the Uganda National Council for Science and Technology under respective references 
FF; GC/127/12/04/22 and HS364, FSW; GC127/12/06/01 and HS1584 approved the conduct of the observational 
(non-SiVET) cohorts and SiVET protocols. A written informed consent was sought from each participant before 
enrolment into a given study. All participants that became HIV positive while in follow-up were immediately 
referred to an HIV treatment and care provider of their choice within the respective study community.
Study methods confirmation. We confirm that all methods in this manuscript were performed in 
accordance with the relevant guidelines and regulations.
Results
Screening and enrolment. Pre‑SiVET. We screened 5902 volunteers and enrolled 3989 (67.6%) partici-
pants into the three observational cohorts before any screening was done for the SiVETs. The primary reasons 
for observational cohort screen failure included; HIV positive (n = 739), low risk for HIV infection (n = 681) 
and not engaged in sex work (FSW observational cohort only, n = 430), Fig. 2. A total of 3622 (90.8%) of those 
enrolled returned for at least one follow-up visit contributing data to the estimation of HIV incidence pre-SiVET.
SiVET concurrent. Of the participants that returned for at least one follow-up visit in the observational cohort 
pre-SiVET, 1525 (42.1%) were eligible for screening for SiVET when the SiVET protocol began. The primary 
reason for ineligibility included being in the observational cohort pre-SiVET for > 18 months, Fig. 2. In total 672 
participants were consecutively screened until 572 (85.1%) were enrolled into SiVET, a screening enrolment 
ratio of 5:4. The primary reasons for screen failure included: previous exposure to Hepatitis B virus (n = 52) and 
unwillingness to use reliable contraception (n = 9). Therefore, 953 participants remained in follow up in the non-
SiVET cohort in the SiVET concurrent period, Fig. 2.
Participants’ baseline characteristics
Pre-SiVET period. Before propensity score matching. Comparing the baseline data of the participants in 
the SiVET to those in the non-SiVET, SiVET had more males; 35.8% vs 30.6%, more who were aged 25 + years; 
69.8% vs 60.4%, more who reported secondary education or more; 30.9% vs 21.2%, those in the fishing or related 
occupations; 29.5% vs 21.4% and more long-term residents; 82.7% vs 75.9%. Additionally, SiVET had more 
participants with ≥ 2 sexual partners in the last 3 months; 66.1% vs 56.5%, Table 1. The standardized difference 
in the covariates between SiVET and non-SiVET ranged between 0.1% in the alcohol use covariate and 22.3% in 
the education level covariate, Table 1.
After propensity score matching. After propensity score matching, comparing SiVET to non-SiVET, all the 
covariates matched on in the two cohorts were comparable (all p-values > 0.05), Table 1. Similarly, the standard-
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ized difference in the covariates between SiVET and non-SiVET became minimal i.e. ranging between 0.7% in 
the number of sexual partners in the last 3 months covariate and 9.0% in the religion covariate, Table 1.
SiVET concurrent period. Before propensity score matching. At baseline, comparing SiVET to non-
SiVET, we observed significant differences in the number of males; 35.8% vs 14.4%, participants aged 25 + years; 
69.8% vs 54.8%, participants with secondary education or more; 30.9% vs 18.3%, those in the fishing and related 
occupations; 29.5% vs 13.0%, long-term community residents; 82.7% vs 66.6%, those reporting one or no sexual 
partner; 33.9% vs 20.8%, respectively (Table 2). The standardized difference in the covariates between SiVET and 
non-SiVET ranged between 0.8% in the religion covariate and 51.1% in the sex covariate, Table 2.
After propensity score matching. After propensity score matching, comparing SiVET to non-SiVET cohorts, all 
the covariates matched on in the two cohorts were comparable (all p-values > 0.05), Table 2 and the standardized 
difference in the covariates between SiVET and non-SiVET became minimal i.e. ranging between 0.0% in the 
education level covariate and 10.4% in the source population covariate.
Standardized bias across covariates. Figure 3, shows the standardized bias across covariates resulting 
from the selection differences between SiVET and non-SiVET cohorts stratified by period (SiVET concurrent 
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bias across all covariates varied across a wide range in the unmatched data (shown by a “•” symbol) while it is 
closer to zero in the matched data (shown by “x” symbol).
HIV incidence in the SiVET concurrent and Pre-SiVET periods. We observed that the point estimate 
for HIV incidence was higher in the non-SiVET compared to SiVET cohorts in both periods; this only achieved 
statistical significance for the SiVET concurrent period. Pre-SiVET: 4.5 /100 Person Years at Risk (PYAR) [95% 
CI 3.8–5.5] vs. 3.5 /100PYAR [95% CI 2.2–5.6], p = 0.161 and SiVET concurrent: 5.9 /100PYAR [95% CI 4.3–8.1] 
vs. 3.5 /100PYAR [95% CI 2.2–5.6], p = 0.033. Before propensity score matching, the results suggest that partici-
pation in SiVET showed a decrease in HIV incidence of approximately 23% and 40% from that observed in the 
non-SiVET in the pre-SiVET and SiVET concurrent periods respectively. After propensity score matching, point 
estimates for HIV incidence were closer together in the SiVET and non-SiVET observational cohort in either 
period, Table 3.
Discussion
In this analysis, we used propensity score matching to create a counterfactual group from observational data with 
baseline covariates comparable to those of participants in a SiVET. The observational cohort data were stratified 
into two periods; pre-SiVET and SiVET concurrent. We found an imbalance in baseline characteristics between 
Table 1.  Baseline characteristics and covariate balance (non-SiVET vs SiVET) in the pre-SiVET period. SiVET 
simulated vaccine efficacy trial, Std (diff) standardized difference, FF fisherfolk, FSW female sex worker.
Variables
Before propensity score matching After propensity score matching
Non-SiVET 
(n = 2928) SiVET (n = 572) p-value Std (diff)
Non-SiVET 
(n = 572) SiVET (n = 572) p-value Std (diff)
Source popula-
tion 0.049 0.090 0.595 0.031
FF 1,575 (53.8) 282 (49.3) 291 (50.9) 282 (49.3)
FSW 1,353 (46.2) 290 (50.7) 281 (49.1) 290 (50.7)
Sex 0.014 0.111 0.540 0.036
Male 896 (30.6) 205 (35.8) 215 (37.6) 205 (35.8)
Female 2,032 (69.4) 367 (64.2) 357 (62.4) 367 (64.2)
Age (years)  < 0.001 0.198 0.897 0.008
18–24 1,160 (39.6) 173 (30.2) 171 (29.9) 173 (30.2)
25 + 1,768 (60.4) 399 (69.8) 401 (70.1) 399 (69.8)
Ethnicity 0.114 0.072 0.813 0.014
Baganda 1,333 (45.5) 281 (49.1) 277 (48.4) 281 (49.1)
Other 1,595 (54.5) 291 (50.9) 295 (51.6) 291 (50.9)
Education  < 0.001 0.223 0.797 0.015
Primary/none 2,307 (78.8) 395 (69.1) 399 (69.8) 395 (69.1)
Secondary + 621 (21.2) 177 (30.9) 173 (30.2) 177 (30.9)
Religion 0.681 0.019 0.185 0.090
Christian 2,255 (77.0) 436 (76.2) 460 (80.4) 436 (76.2)
Muslim 673 (23.0) 136 (23.8) 112 (19.6) 136 (23.8)
Marital status 0.867 0.008 0.894 0.008
Single (never 
married) 788 (26.9) 152 (26.6) 154 (26.9) 152 (26.6)
Current/previ-
ously married 2,140 (73.1) 420 (73.4) 418 (73.1) 420 (73.4)
Occupation  < 0.001 0.187 0.747 0.019
Fishing/related 627 (21.4) 169 (29.5) 174 (30.4) 169 (29.5)
Other (non-
fishing) 2,301 (78.6) 403 (70.5) 398 (69.6) 403 (70.5)
Duration (years) lived in com-
munity  < 0.001 0.169 0.635 0.028
0–1 706 (24.1) 99 (17.3) 93 (16.3) 99 (17.3)
 > 1 2,222 (75.9) 473 (82.7) 479 (83.7) 473 (82.7)
Alcohol use (last 3-month) 0.992 0.001 0.580 0.033
No 1,091 (37.3) 213 (37.2) 204 (35.7) 213 (37.2)
Yes 1,837 (62.7) 359 (62.8) 368 (64.3) 359 (62.8)
Number of partners (last 3-month)  < 0.001 0.198 0.900 0.007
0–1 1,274 (43.5) 194 (33.9) 192 (33.6) 194 (33.9)
2 + 1,654 (56.5) 378 (66.1) 380 (66.4) 378 (66.1)
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non-SiVET and SiVET cohorts in the pre-SiVET and SiVET concurrent periods. In both periods, SiVET partici-
pants were mainly men (FF), ≥ 25 years, long-term residents, more educated and reported fewer sexual partners 
in the last three months (SiVET period). These characteristics have been associated with low HIV incidence 
in  these30–34 and  other35–38 key populations. Consequently, the HIV incidence was lower in the SiVET cohorts 
compared to non-SiVETs in both periods, more so in the SiVET concurrent period.
Studies14–17 have shown that propensity score analysis can create a balance in participants’ characteristics 
between the treated and untreated groups, providing a unique opportunity to compare unbiased outcomes 
between these groups. Using propensity score matching, we created a non-SiVET counterfactual arm with par-
ticipants’ baseline characteristics comparable to SiVET in both periods. Although the HIV incidence was still 
lower in the SiVET cohorts, the difference in HIV incidence between non-SiVET and SiVET cohorts narrowed, 
respectively from 23 to 15% in the pre-SiVET and from 41 to 11% in the SiVET concurrent.  Studies10,39 have 
previously indicated that trial volunteers are more likely to positively respond to HIV risk reduction measures 
such as condom use, reduction in the number of sexual partners and starting new sexual relationships among 
others. In addition, trials provide packages including treatment for sexually transmitted infections and active 
tracing of participants to keep them in follow up. These interventions have been shown to be associated with 
diminished HIV incidence even in absence of an efficacious investigational product or absence of an imbalance 
in the participant baseline characteristics between the treated and untreated  arms39,40. As previously  reported23, 
Table 2.  Baseline characteristics and covariate balance (non-SiVET vs SiVET) in the concurrent period. 
SiVET simulated vaccine efficacy trial, Std (diff) standardized difference, FF fisherfolk, FSW female sex worker.
Variables
Before propensity score matching After propensity score matching
Non-SiVET 
(n = 953) SiVET (n = 572) p-value Std (diff)
Non-SiVET 
(n = 469) SiVET (n = 469) p-value Std (diff)
Source popula-
tion  < 0.001 0.409 0.112 0.104
FF 283 (29.7) 282 (49.3) 208 (44.3) 184 (39.2)
FSW 670 (70.3) 290 (50.7) 261 (55.7) 285 (60.8)
Sex  < 0.001 0.511 0.235 0.078
Male 137 (14.4) 205 (35.8) 131 (27.9) 115 (24.5)
Female 816 (85.6) 367 (64.2) 338 (72.1) 354 (75.5)
Age (years)  < 0.001 0.313 0.489 0.045
18–24 431 (45.2) 173 (30.2) 152 (32.4) 162 (34.5)
25 + 522 (54.8) 399 (69.8) 317 (67.6) 307 (65.5)
Ethnicity 0.018 0.125 0.647 0.030
Baganda 409 (42.9) 281 (49.1) 230 (49.0) 223 (47.5)
Other 544 (57.1) 291 (50.9) 239 (51.0) 246 (52.5)
Education  < 0.001 0.298 1.000 0.000
Primary/none 779 (81.7) 395 (69.1) 334 (71.2) 334 (71.2)
Secondary + 174 (18.3) 177 (30.9) 135 (28.8) 135 (28.8)
Religion 0.874 0.008 0.878 0.010
Christian 723 (75.9) 436 (76.2) 358 (76.3) 360 (76.8)
Muslim 230 (24.1) 136 (23.8) 111 (23.7) 109 (23.2)
Marital status 0.002 0.167 0.716 0.024
Single (never 
married) 326 (34.2) 152 (26.6) 128 (27.3) 133 (28.4)
Current/previ-
ously married 627 (65.8) 420 (73.4) 341 (72.7) 336 (71.6)
Occupation  < 0.001 0.412 0.213 0.081
Fishing/related 124 (13.0) 169 (29.5) 115 (24.5) 99 (21.1)
Other (non-
fishing) 829 (87.0) 403 (70.5) 354 (75.5) 370 (78.9)
Duration (years) lived in com-
munity  < 0.001 0.376 0.626 0.032
0–1 318 (33.4) 99 (17.3) 92 (19.6) 98 (20.9)
 > 1 635 (66.6) 473 (82.7) 377 (80.4) 371 (79.1)
Alcohol use (last 3-month) 0.001 0.179 0.270 0.072
No 275 (28.9) 213 (37.2) 167 (35.6) 151 (32.2)
Yes 678 (71.1) 359 (62.8) 302 (64.4) 318 (67.8)
Number of partners (last 3-month)  < 0.001 0.298 0.168 0.090
0–1 198 (20.8) 194 (33.9) 142 (30.3) 123 (26.2)
2 + 755 (79.2) 378 (66.1) 327 (69.7) 346 (73.8)
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SiVET participants received more HIV risk reduction measures than their non-SiVET counterparts and con-
sequently achieved higher reduction in HIV risk behavior,  reported23. These interventions or chance could be 
responsible for the 10% to 15% observed reductions in HIV incidence in SiVET vs non-SiVET in both periods 
after removing the imbalance in participants’ baseline characteristics.
The results of this analysis suggest that propensity score matching can help create a counterfactual trial arm 
from observational data especially in the concurrent period where participants in the trial have similar follow 
up conditions (aligned to the same duration of follow up) as those in the source population. Furthermore, in a 
PrEP and ART demonstration project, investigators found HIV incidence that was lower than that in the coun-
terfactual group derived from prior prospective studies in similar key  populations41. This further confirms that 
counterfactual groups if well-constructed can be used to assess efficacy and/or effectiveness in clinical trials and 
routine setting. Taking results of this analysis and previous studies, counterfactual group HIV incidence can be 
a useful tool for assessing efficacy in trials where new HIV prevention products are tested against active com-
parators like in HPTN  08342 and HPTN  08443 or trials providing interventions to all participants like in HPTN 
 08244. In the future HIV prevention trials where combination prevention is a key requirement in the conduct 
of clinical trials, use of propensity score matching will come in handy when creating a counterfactual arm to 
estimate treatment effects using data from observational cohorts gathered in the concurrent or previous period 
(in absence observational cohort data in the concurrent period).
The strengths of our analysis include; a large sample size of observational data in the pre-SiVET and SiVET 
concurrent periods to provide propensity score matches to SiVETs participants, and two distinct source popula-
tion cohorts located in different geographical places. Having a SiVET concurrent period provided us a unique 
opportunity to compare trial-targeted outcomes aligned to adjust to the same duration of time. Additionally, 
the same study staff in the different source populations implemented non-SiVET and SiVET protocols, avoiding 
observer variation. These studies also provided us with a rare trial environment opportunity similar to a trial 
placebo arm in an era of widespread use of active trial control arms.
Our studies are not without limitations; although SiVETs had somewhat different protocols from the non-
SiVET cohorts, the same study staff implemented them. This could have introduced some unmeasured bias 
arising from differentials in the completion of study procedures. However, at the time of the conduct of SiVETs 
and non-SiVETs, the primary objective was not to compare outcomes between the two and therefore differences 
in the completion of the studies procedures could have been minimal. By design, SiVET participants received 
Figure 3.  Standardized differences across covariates: pre-matching and post-matching.
Table 3.  HIV incidence by study period before and after propensity score matching. PSM propensity score 




ratio (95% CI) p-valueHIV + PYAR 
Incidence (95% 




Before PSM 17 484.9 3.5 (2.2–5.6) 39 658.1 5.9 (4.3–8.1) 0.59 (0.31–0.68) 0.033
After PSM 16 386.0 4.1 (2.5–6.8) 20 428.1 4.7 (3.0–7.2) 0.89 (0.43–1.80) 0.364
Pre-SiVET
Before PSM 17 484.9 3.5 (2.2–5.6) 105 2309.7 4.5 (3.8–5.5) 0.77 (0.43–1.29) 0.161
After PSM 17 484.9 3.5 (2.2–5.6) 18 436.1 4.1 (2.6–6.6) 0.85 (0.41–1.75) 0.316
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more HIV risk reduction counseling because of frequent visits to the clinic. This could have caused differentials 
in the participant response to HIV risk reduction measures. However, in an actual HIV vaccine efficacy trial, it 
is expected that participants will have more frequent clinic visits for safety assessments and HIV risk reduction 
counselling than in the routine observational data. Furthermore, we informed the participants that the Hepatitis 
B vaccine provided would prevent hepatitis B infection and not HIV acquisition; this could have encouraged 
more of those with good health seeking behavior to keep coming to the study clinic for follow up.
Conclusion
In these key populations, the process of screening for eligibility for HIV vaccine efficacy trial selects participants 
with baseline characteristics different from those excluded or not screened. This could result in an HIV inci-
dence different from source population even in absence of an effective investigational product. Propensity score 
matching can be a useful tool to minimise the imbalance in the participants’ baseline characteristics between 
participants joining the trial and those not, making the two groups comparable. In light of HIV prevention trials 
having active control, investigators could consider using propensity score matching to have a counterfactual (non-
randomised) arm but comparable trial arm in the source population to compare HIV incidence and estimate 
treatment effects. However, this will require concurrent measurement of HIV infection in the source population 
to remove the impact of development and/or time on HIV incidence. Where such data is unavailable, pretrial 
registration cohorts or other existing cohorts in the same or similar populations could provide some insights 
into the source population HIV incidence.
Data availability
The MRC/UVRI and LSHTM Uganda Research Unit encourages data sharing and has a published (https:// www. 
mrcug anda. org/ publi catio ns/ data- shari ng- policy) data sharing policy. This policy summarizes the conditions 
under which data collected by the Unit can be made available to other bona fide researchers, the way in which 
such researchers can apply to have access to the data and how data will be made available if an application for 
data sharing is approved. Should any of the other researchers need to have access to the data from which this 
manuscript was generated, the processes to access the data are well laid out in the policy. The corresponding 
and other co-author emails have been provided and could be contacted anytime for any clarifications and/or 
support to access the data.
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